Gastric cancer trends in Estonia 1995–2014 by age, subsite, morphology and stage

Authors

  • Mari-Leen Pärn Department of Hematology and Oncology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia
  • Kaire Innos Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia
  • Aleksei Baburin Department of Epidemiology and Biostatistics, National Institute for Health Development, Tallinn, Estonia
  • Raul-Allan Kiivet Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia
  • Jana Jaal Department of Hematology and Oncology, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia; ;Department of Radiotherapy and Oncological Therapy, Haematology and Oncology Clinic, Tartu University Hospital, Tartu, Estonia

DOI:

https://doi.org/10.1080/0284186X.2018.1546058

Abstract

Background: Gastric cancer (GC) is among the most common cancers and one of the leading causes of cancer deaths globally. In general, the incidence of GC has declined and survival improved in Europe. Nevertheless, previous analysis has shown that survival of GC patients in Estonia is still significantly lower compared to some European countries. Therefore, to improve patient outcomes, better overview of GC epidemiology is needed. The aim of this study was to describe the incidence and survival of GC in Estonia 1995–2014 in relation to age, subsite, morphology, and the extent of disease.

Material and methods: We used data from the population-based Estonian Cancer Registry on all incident cases of GC diagnosed in 1995–2014. Incidence rates and relative survival were calculated. Joinpoint regression modeling was used to estimate annual percentage change for incidence trends. Data were analyzed by age, sex, subsite, morphology, and the extent of disease. Changes between 1995–1999 and 2010–2014 were assessed.

Results: The overall incidence of GC in Estonia decreased in 1995–2014. The age-standardized (world) incidence declined significantly for both sexes, for patients below 70 years of age, adenocarcinomas, NOS and other morphologies, non-cardia and unspecified cases, and for all known stages. Approximately 40% of GC cases were diagnosed with distant metastasis. Overall age-standardized 5-year relative survival of GC patients increased from 20% to 28%. Survival improved the most in age group 50–69 years. A large survival gain was also seen for localized (from 55% to 70%) and locally/regionally spread disease (from 23% to 37%).

Conclusions: In Estonia, the incidence of GC has declined and relative survival increased. However, special emphasis needs to be put on improving survival among men, elderly and in patients with metastatic disease.

Downloads

Download data is not yet available.

Downloads

Published

2019-03-04

How to Cite

Pärn, M.-L. ., Innos, K. ., Baburin, A. ., Kiivet, R.-A. ., & Jaal, J. . (2019). Gastric cancer trends in Estonia 1995–2014 by age, subsite, morphology and stage. Acta Oncologica, 58(3), 283–289. https://doi.org/10.1080/0284186X.2018.1546058